The filing discloses positive Phase 3 trial results for Cemdisiran, a drug developed by Regeneron and Alnylam, showing significant improvements in daily functioning and muscle strength for patients. This positive data increases the likelihood of FDA approval, which is expected in November 2026, potentially opening up a new revenue stream for both companies.
Regeneron and Alnylam announced positive Phase 3 trial results for their drug Cemdisiran, which demonstrated significant improvements in patients with generalized myasthenia gravis. This is a crucial development as it substantially de-risks the drug's path to market, increasing the probability of FDA approval. The positive data is a strong catalyst for both companies, as a successful drug launch could lead to significant revenue growth in the long term. For traders, this presents an opportunity for upside in REGN and ALNY stock, particularly as the FDA decision approaches in November 2026. The key risk is that the FDA could still reject the drug, or competitors could emerge with superior treatments.